Kyowa Hakko’s Parkinson’s Drug Is Not Approvable – U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko will work with U.S. FDA to determine a path forward for its Parkinson's treatment istradefylline (KW-6002) after receiving a "not approvable" letter from the agency Feb. 25, the Tokyo-based firm said Feb. 27
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy
Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.
Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy
Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.